In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.
Vertex Pharmaceuticals Incorporated has taken another step to expand beyond its market-leading cystic fibrosis (CF) franchise by linking up with Skyhawk Therapeutics, Inc. and its RNA-splicing technology.
The companies have been fairly coy about the details, simply stating that that their alliance is aimed at "the discovery and development of novel small molecules that modulate RNA splicing for the treatment of serious diseases," using Skyhawk's SkySTAR platform
An ‘historic economic prosperity deal’ does not include the sector.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
